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Abstract
Purpose In patients with a high life expectancy at the time of
surgery for colorectal cancer (CRC), the long-term outcome
may be influenced by factors other than their cancer. We
aimed to investigate the long-term outcome and cause of death
beyond a 5-year surveillance programme.
Methods We evaluated the overall survival (OS) and cancer-
specific survival (CSS) of a population-based cohort of stage
I–III CRC patients <75 years old who completed a systematic
surveillance programme.
Results In total, 161 patients <75 years old, 111 (69 %) of
whom were node negative (pN0), were included. The median
follow-up time was 12.1 years. The OS was 54 % at 15 years
and differed significantly between the pN0 and pN+ patients
(65 vs. 30%; P<0.001); CSS (72%) also differed between the
pN0 and pN+ patients (85 vs. 44 %; P<0.001). For the 5-year
survivors (n=119), 14 (12 %) died of CRC during additional
long-term follow-up (7 each for pN0 and pN+), and 6 patients
(5 %; all pN0) died of other cancers. Patients aged <65 years
exhibited better long-term survival (81 %), but most of the
deaths were due to CRC (10/12 deaths). Only two of the 14
cancer-related deaths involved microsatellite instable (MSI)
CRC. Females exhibited better OS and CSS beyond 5 years
of surveillance.
Conclusions The long-term survival beyond 5-year survivor-
ship for stage I–III CRC is very good. Nonetheless, cancer-
related deaths are encountered in one-third of patients and
occur most frequently in patients who are <65 years old at
disease onset—pointing to a still persistent risk several years
after surgery.
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Introduction
Colorectal cancer (CRC) is a leading cause of cancer-related
morbidity and mortality in the Western world. The prognosis
for CRC has increased considerably with the development of
better staging, improved surgical techniques and adjuvant
therapy [1–3]. Indeed, the 5-year survival rates have never
been better, and survival in rectal cancer has now even
surpassed that of colon cancer [4]. Cancer-specific survival
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for all colorectal patients now exceeds 60 % when a curative
resection is performed [1, 4–8]. Overall, the presence of
lymph node metastasis is one of the strongest prognostic fac-
tors in CRC, but the appropriate therapy remains a controver-
sial and much-debated topic [9]. Patients with node-negative
disease (pN0) have excellent prognoses, but up to 10–20 % of
cases may nonetheless recur, develop distant metastasis and
eventually die from disseminated disease [10]. Even T1 node-
negative disease patients exhibit a 7–8% risk of cancer-related
death at the 10-year follow-up [11].
Systematic surveillance has been suggested to detect
asymptomatic recurrences at a curable stage; however,
the evidence for this approach and the potential
follow-up strategies remain debated [12]. First, the
choice of modality for surveillance is unclear, although
some form of imaging and monitoring with tumour
markers (i.e., carcinoembryonic antigen; CEA) is used.
However, this method of surveillance is not currently
tailored to the individual patient’s risk for recurrence
[13]. Second, the recurrence pattern and mortality risk
may differ throughout the course of follow-up, which is
demonstrated by the time differences in colon and rectal
cancer mortality [14]. Third, patients presenting with
cancer at a young age may have a different disease
pattern and recurrence risk than elderly patients [15].
Indeed, although the 5-year follow-up is satisfactory in
patients who are elderly, with limited long-term longev-
ity, the younger patient population may exhibit an in-
creased lifetime risk for both disease recurrence and
death from disease. However, very little data exist on
very long-term outcomes for the younger (<75 years old
at diagnosis) population of patients with colorectal can-
cer, and there is even less information concerning pa-
tients who are <65 years old. As the expected lifespan
is currently increasing (approaching over 80 years of
age for both genders in Norway) [16], it is increasingly
important to determine the long-term survival of the
youngest (e.g. <75 years of age) CRC patients who
are curatively treated.
Consequently, the aim of this study was to examine the
very long-term (up to 15 years) survival of CRC patients after
curative resection, specifically survival beyond 5 years, in a
systematic surveillance programme after surgery.
Methods
The study was approved as a quality assurance project
(REK#2010/3414) by the Regional Ethics Committee of the
Health Trust of Western Norway. Informed consent was
waived because this was a quality assurance of clinical
practice.
Study Cohort and Background
The study cohort included a set of long-term follow-up pa-
tients who have been thoroughly described elsewhere [17].
Briefly, all patients with CRC who underwent operations at
Stavanger University Hospital between July 1996 and
June 1999 were included in this study. Stavanger University
Hospital serves as the only hospital for the population in the
region, with an estimated 280,000 inhabitants at the time the
study commenced.
During the study period, 314 patients had curative treat-
ment, and 194 of these patients were enrolled in a postopera-
tive systematic follow-up programme according to the
existing guidelines from Norwegian Gastrointestinal Cancer
Group (NGICG) [18]. The follow-up was based on regular
CEA-monitoring, chest X-ray, liver ultrasound, and 1- and
5-year colonoscopy [17, 19].
Inclusion and Exclusion Criteria
All 194 patients who had an R0 resection (defined as free
resection borders by microscopy) for colon or rectal cancer
and were included in the systematic surveillance programme
were eligible. Further, patients with available DNA for micro-
satellite instability (MSI) analysis were included (n=186,
96 % of the 194), as previously reported [3]. Those patients
who were <75 years at the time of primary diagnosis were
included in the current study.
Follow-Up Beyond 5 Years After Curative Surgery
The follow-up was performed by searching the hospital’s elec-
tronic and paper records for information. All patients in Nor-
way have an 11-digit social security number linked to several
population-based registries, including the Cause of Death reg-
istry. The Cause of Death registry is connected to the hospital
electronic system, and a registered death (and date of death) of
a patient is immediately marked in the electronic hospital files
(if death occurs in the hospital) or is marked within a short lag
time if the death occurs outside the hospital or in another
geographic area. Therefore, we were able to detect all deaths
that occurred until an arbitrarily set date 3 weeks before the
final follow-up date of July 23, 2011. Patients were followed
until the date of the final follow-up or until death from cancer
or another disease. Patients who were lost to follow-up
(moved out of the country) were censored with last known
hospital contact as the final date.
Descriptive Data and Characteristics
Cancers were histopathologically staged according to the
tumour-node-metastasis (TNM) classification system (5th re-
vision) at the time. Location in the colorectum was defined as
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‘proximal’ or ‘distal’; proximal cancers included cancers lo-
cated from the caecum to the left flexure, and distal cancers
were located from the descending colon to the rectum. Pre-
and postoperative CEA values were registered and obtained
by routine laboratory workup before and after surgery, as pre-
viously reported [19, 20]. The preoperative ASA score was
recorded. All patients had their MSI status analysed using a
PCR-based technique, which was determined according to
standard criteria, as previously described [19].
Study Endpoint
The primary endpoint of the current investigation was cancer-
specific long-term survival more than 5 years after completing
a systematic surveillance programme as well as overall sur-
vival (defined as death from any cause). Additionally, we
wanted to record any type of fatal event to compare the overall
survival (e.g. fromCRC, a new other malignancy, or any other
causes) for the youngest group (those <65 years of age at the
Table 1 Study characteristics of
all patients and long-term
survivors
Descriptive All patients, n=161 (%) Long-term survivors, n=119
Age (median, IQR; years) 64.5 (57.9–69.9) 63.7 (57.6–69.9)
<65 years 83 (52 %) 62 (52 %)
≥65 to 75 years 78 (48 %) 57 (48 %)
Gender
Male 98 (61 %) 73 (61 %)
Female 63 (39 %) 46 (39 %)
ASA scorea
I 92 (57 %) 71 (61 %)
II 57 (35 %) 41 (35 %)
III 10 (6 %) 5 (4 %)
>II 0 0
TNM stage
I 27 (17 %) 23 (19 %)
II 84 (52 %) 70 (59 %)
III 50 (31 %) 26 (22 %)
Location
Colon 103 (54 %) 73 (61 %)
Rectum 58 (36 %) 46 (39 %)
Grade
High/moderate 140 (87 %) 108 (91 %)
Low/mucinous 21 (13 %) 11 (9 %)
T stage
T1–2 33 (20.5 %) 27 (23 %)
T3–4 128 (79.5 %) 92 (77 %)
MSI status
MSI 36 (22 %) 25 (21 %)
MSS 125 (78 %) 94 (79 %)
CEA pre-opb 3.0 (1.0–6.0) 3.0 (1.0–7.0)
≤4 94 (67 %) 71 (66 %)
>4 47 (33 %) 36 (34 %)
CEA post-opb 1.0 (1.0–2.0) 1.0 (1.0–2.0)
≤4 131 (89 %) 99 (88 %)
>4 17 (12 %) 13 (12 %)
Data are presented as the median with interquartile ranges or numbers with rates (%). Percentages may not add up
due to rounding
ASA American Society of Anesthesiology fitness class, MSI microsatellite instability, CEA carcinoembryonic
antigen
a Data missing from two patients
b Based on patients with available data
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primary diagnosis) with the oldest group (≥65 years but
<75 years old at the primary diagnosis). For cancer-specific
survival, the non-cancer-related deaths were censored in the
survival analysis.
Statistical Analyses
Statistical analyses were performed using the IBM Statistical
Package for Social Sciences, version 21 (SPSS v. 21). De-
scriptive data are presented as the median and interquartile
range (IQR) for continuous variables, or when appropriate,
dichotomised. Survival analyses were performed using the
Kaplan-Meier method and log rank test. All tests were two-
tailed, and P values <0.050 were considered statistically
significant.
Results
Overall Outcome for Stage I–III Patients
In total, 161 patients met the inclusion criteria and were
≤75 years old at diagnosis; their clinical characteristics are
presented in Table 1. The median follow-up was 12.1 years
(interquartile range 4.8–13.4 years). The 5-year overall sur-
vival was 72 % (n=116), and the 5-year cancer-specific sur-
vival was 88 % (n=123) for all stages (Table 2). The long-
term (up to 15 years) overall survival was 54% (n=89), which
differed significantly between stage I/II (63 and 66 %) and
stage III (30 %; P<0.001). The cancer-specific survival for
all stages is depicted in Fig. 1 and Table 2.
Long-Term Survivors After 5-Year Surveillance
In total, 119 patients (74 %) survived beyond 5 years after
diagnosis and were therefore subject to long-term analyses.
For this sub-cohort, the median age was 63.7 years
Table 2 Cancer-specific survival







Age <65 years 62 80.6 % (50) 16.1 % (10) 0.197
≥65 years 57 63.2 % (36) 7.0 % (4)
Gender Male 73 65.8 % (48) 16.4 % (12) 0.041
Female 46 82.6 % (38) 4.3 % (2)
TNM stage I+II 93 77.4 % (72) 7.5 % (7) 0.002
III 26 53.8 % (14) 26.9 % (7)
Location Distal 83 71.1 % (59) 10.8 % (9) 0.664
Proximal 36 75.0 % (27) 13.9 % (5)
Location Colon 73 79.5 % (58) 8.2 % (6) 0.113
Rectum 46 60.9 % (28) 17.4 % (8)
MSI status MSI 25 84.0 % (21) 8.0 % (2) 0.483
MSS 94 69.1 % (65) 12.8 % (12)
Grade High/moderate 108 70.4 % (76) 13.0 % (14) 0.233
Low/mucinous 11 90.9 % (10) 0
T stage 1+2 27 70.4 % (19) 11.1 % (3) 0.892
3+4 92 72.8 % (67) 12.0 % (11)
Fig. 1 Stage-dependant, cancer-specific, long-term survival for all pa-
tients who were <75 years old at diagnosis. Stage-dependant survival is
depicted. The grey dotted vertical line parallel to the x-axis denotes the 5-
year point at which systematic surveillance after surgery ended. The cor-
responding grey dotted horizontal lines on the y-axis indicate the corre-
sponding stage-dependant survival at 5 years
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(interquartile range 57.6–70.0) with a similar distribution
of younger (<65 years) and older (>65 to 75 years) pa-
tients (52 and 48 %, respectively) (Table 3). Males
accounted for 61 % (73/119) of the patients, and the ma-
jority of patients had node-negative disease at diagnosis.
Twenty-three (19.3 %) patients had stage I disease, 70
(58.8 %) patients had stage II disease and 26 (21.8 %)
patients had stage III disease.
Cause of Death in Long-Term Survivors After 5 Years
of Surveillance
In total, 33 of the 119 patients died during the follow-up pe-
riod after 5 years of surveillance. CRC was the cause of death
in 14 patients, whereas 13 and 6 patients died of other causes
(e.g., heart disease) and other cancers, respectively. Ten of the
14 patients who eventually died of CRC had developed recur-
rence within 5 years of surveillance. For those who had not
died of CRC at the end of the long-term follow-up, a further 9
had developed recurrence, 7 of whom were alive and 2 of
whom had died from other causes. Lung cancer, lymphoma
and pancreatic cancer were the other cancers that resulted in
death, and 2 patients died of a cancer of unknown origin. For
the 13 patients who died of other causes, 6 patients died of
cardiovascular disease.
Long-Term Overall and Cancer-Specific Survival
For the long-term survivors, overall survival at 15 years was
72 %, and the difference was significant between stages I/II
(74 and 79 %, respectively) and III (54 %; P=0.024). When
comparing node-negative and node-positive disease, survival
at 15 years was 77 vs. 54 % (P=0.007) (Table 4). Univariate
cancer-specific survival beyond 5 years of surveillance is pre-
sented in Table 2. Only gender (Fig. 2) and TNM stage were
significant predictors of survival.
For long-term survivors who were <65 years old at diag-
nosis, 50/62 (81 %) were alive at the end of follow-up, and 10
out of 12 deaths were related to CRC in this group. In patients
who were >65 years old at diagnosis, 63 % were alive at the
end of follow-up, and only 4 of 21 deaths were related to
CRC.
The difference in the cancer-specific mortality was not sig-
nificant. Altogether (Table 2), 12 men and only 2 women died
of CRC after 5 years of systematic surveillance. In the univar-
iate analysis, only female gender (P=0.041) and TNM stage
(P=0.002) predicted cancer-specific survival after 5 years
(Table 2).
Microsatellite instability (MSI) was detected in the tumours
of 25 (21 %) patients. Within the node-negative group, 24 %
of tumours exhibited MSI, whereas only 11 % of tumours
exhibited MSI in the node-positive group. In the younger
Table 3 Outcomes after the 5-year follow-up according to age at diagnosis
Age groups Median follow-up Total (n)
<65 years 65 to 75 years
Follow-up status Alivea 50 (81 %) 36 (63 %) 13.2years 86 (72%)
Dead from CRC 10 (16 %) 4 (7 %) 7.6years 14 (12%)
Dead from another cancer 1 (2 %) 5 (9 %) 9.3years 6 (5%)
Dead from another cause 1 (2 %) 12 (21 %) 10.1years 13 (11%)
Total 62 (52 %) 57 (48 %) 119
aAlive at the end of follow-up; not censored for death from CRC, another cancer or another cause. The percentages may not add up due to rounding
Table 4 Outcomes after the 5-
year follow-up according to node
status
Node status Total
Node negative Node positive
Follow-up status Alivea 72 (77 %) 14 (54 %) 86 (72%)
Dead from CRC 7 (8 %) 7 (27 %) 14 (12%)
Dead from another cancer 6 (7 %) 0 6 (5%)
Dead from another cause 8 (9 %) 5 (19 %) 13 (11%)
Total 93 (78 %) 26 (22 %) 119
The percentages may not add up due to rounding
a Alive at the end of follow-up; not censored for death from either CRC, another cancer, or another cause
J Gastrointest Canc (2015) 46:259–266 263
patient group (<65 years old), more patients had MSI tumours
than in the older group (>65 years), with rates of 27 % (17/62)
and 14 % (8/57), respectively (Fig. 3). For patients who were
alive after 5 years of follow-up, 14 died of CRC, and 10 were
younger than 65 years. Only 2 of those younger than 65 years
old who died of CRC exhibited MSI in their primary tumours.
Discussion
This long-term study of patients who survived beyond 5 years
after systematic surveillance demonstrated an overall good
prognosis for node-negative disease. However, 12 % of pa-
tients died from CRC, and the numbers were equally distrib-
uted between node-negative and node-positive cancer cases.
Notably, the majority of CRC-related deaths occurred in pa-
tients whowere <65 years old at diagnosis, possibly indicating
that surveillance is warranted for a longer time period for
certain high-risk patients and that the identification of such
risk factors is useful for tailored follow-up.
One immediate perceived risk in the youngest survivors
would be that of an (undiagnosed) inherited cancer syndrome,
such as hereditary non-polyposis colorectal cancer (HNPCC).
However, based on MSI analysis, only 2 out of the 10 CRC-
related deaths in patients <65 years old were associated with
MSI tumours, and the presence of HNPCC can therefore not
explain the results. One explanation is that younger patients
likely harbour a different, aggressive cancer biology. Alterna-
tively, younger patients may exhibit more senescent or viable
tumour cells that may recur over time or may exhibit an indo-
lent pattern of tumour relapse as observed in some other can-
cer forms (i.e. breast cancer), thereby conferring a higher risk
of cancer-related death on long-term follow-up. Our findings
replicate, to some extent, the previous finding that younger
patients (aged 15–44 years old) with stage III disease had
worse long-term survival after 5 years of follow-up compared
with the other age groups [21]. Additionally, patients with
young-onset (non-hereditary) CRC exhibit a different genetic
profile than older patients [22]. A further explanation may be
that younger patients have a longer expected survival than the
older patients and therefore higher cumulative exposure to
factors that may have caused CRC in the first place (the Bfield
defect^ in the colon), increasing their risk for recurrence or
new cancer. Further investigation into the biology of the per-
sistent cancer risk is warranted.
Long-term survival for patients with CRC is excellent be-
yond the 5 years of follow-up. Up to 5 years, most deaths are
related to CRC, but from 5 to 15 years, the majority of deaths
are related to other cancers or causes, especially in the group
Fig. 2 Cancer-specific, long-term survival for patients alive at the 5-year
follow-up, stratified for men and women. The first 5 years indicate sur-
vival and completed surveillance after surgery. After the 5-year surveil-
lance programme, gender-specific and cancer-specific survival is
depicted
Fig. 3 Flowchart demonstrating
the distribution of long-term sur-
vivors who completed the 5-year
surveillance programme (sug-
gested as a supplementary figure
only if needed due to space re-
strictions). Distribution (n=119)
according to the age groups, MSI
status and cause of death is
depicted. MSI+ microsatellite in-
stability, MSS microsatellite sta-
bility, yrs years, and CRC colo-
rectal cancer-related death
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older than 65 years of age. Cancer-related deaths are most
frequent in the group that is younger than 65 years, but the
majority of patients experienced recurrence before reaching
the end of the 5-year survival. In this study, age did not predict
disease-free survival, although only 16 % (2/12) of deaths in
patients younger than 65 years old were caused by other dis-
eases, which is in contrast with 81 % (17/21) of non-CRC-
related deaths in patients who are ≥65 years old. The prognos-
tic influence of age on survival after 5 years is largely reduced
in several studies [21, 23–25]. Additionally, patients whowere
>75 years old were not included in the current study; we
excluded the group of elderly and frail patients who may die
from various comorbid diseases.
Notably, management and therapy may have changed since
the commencement of patient enrolment in this study. A small
sample size is also a limitation. However, to investigate a
long-term follow-up, a change in management over time is
an inherent problem. The small sample size is in part due to
the selected population; we chose only patients with stage I–
III, a defined curative resection, age <75 years and who had
entered a surveillance programme. This procedure selects for
younger, healthier patients with less disease burden and for
which the overall survival is expected to be very good. This
study reveals that there is still an inherent risk of cancer death
in these patients, and an investigation into the nature and bi-
ology of this finding is warranted. Future studies should also
aim for a larger sample size.
In the present study, the TNM stage predicted cancer-
specific survival. This result is in contrast with a larger Dutch
study from 2007 [24] in which the TNM stage had no predic-
tive value for patients who survived 5 years after diagnosis.
Several other studies demonstrated that as time goes by, stage
loses its prognostic significance when investigated for dura-
tion cut-offs at 5 or 8 years of follow-up after diagnosis [21,
24]. This effect may be because the cancer-specific death rate
declines as the years progress, whereas the rate is the most
prominent for stage III during the early stages of follow-up
(the first 3 years after surgery) [26, 27].
In addition to stage, female gender predicted better cancer-
specific survival after 5 years in the current study. This may be
explained by the larger mortality for females within the first
5 years after diagnosis as well as the higher percentage of
males compared with females who were diagnosed with
TNM stage III. According to the national figures from the
Cancer Registry of Norway, females have better short- and
long-term colon cancer survival than males [28]. The contri-
bution of gender to the prognosis requires further
investigation.
The current study points to a still-present risk factor for
cancer-related events in node-negative CRC, although surviv-
al beyond 5 years remains very good. The strength of the
current study is the population-based approach, wherein we
evaluated a well-defined cohort and performed a complete
follow-up for all causes of death. However, some limitations
are worth noting. The number of patients was limited in this
cohort study, which may have obscured any true statistically
significant results between groups because the sample size per
group was small. Additionally, we cannot rule out other famil-
iar or hereditary genetic risk syndromes because the only mo-
lecular test run for this cohort was the MSI analysis. However,
no hereditary syndromes were reported in any of the patients,
and this shortcoming applies to most other long-term follow-
up studies where genetic testing is not a routine component of
clinical care. Additionally, all patients were relatively young
(<75 years old) at diagnosis; therefore, the cancer-specific
outcome was not obscured by high age-related mortality from
other causes. With the increasing indications for secondary
metastatic surgery for both hepatic and pulmonary metastases
as well as the improved outcomes from adjuvant chemother-
apy, the identification of the patients who are at risk for recur-
rent disease has become increasingly important to tailoring the
best surveillance strategy to the patients’ needs.
Conclusions
Long-term survival beyond the 5-year surveillance period for
stage I–III CRC is very good. Notably, cancer-related deaths
are encountered in one-third of patients. Cancer-related deaths
occur most frequently in patients who are <65 years old at
diagnosis. This finding may warrant further investigation into
long-term survival beyond the usual 5-year surveillance in
patients who are young at their primary diagnosis.
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